The market potential of sucrose ferric hydroxide-hyperphosphatemia clinical demand is huge
2025.01.22
Sucrose ferric hydroxide is a new non-calcium-based phosphate binder with a unique composite structure consisting of polynuclear iron hydroxide and carbohydrates.Sucrose ferric hydroxide contains approximately 20% iron, and clinical trials have confirmed that sucrose ferric hydroxide does not increase the body's iron load and is superior to calcium-based phosphate binders in preventing vascular calcification. It is more suitable for patients with iron deficiency and hyperphosphatemia, and the common adverse reaction is diarrhea.
According to clinical research evaluation, the first three-phase clinical results of sevelamer compared with sucrose ferric hydroxide showed that sucrose ferric hydroxide controlled the hyperphosphatemia of patients with fewer pills/tablets. After 52 weeks, the average daily dose for controlling hyperphosphatemia was only 3.3 pills/day, achieving the primary and secondary endpoints of the study.
Sucrose ferric hydroxide has good therapeutic effects, and the effectiveness and safety of long-term administration have been confirmed in clinical studies, with strong market potential in the future.
Shanghai Gongji Chemicals specializes in producing high-purity pharmaceutical iron trichloride hexahydrate with high content and low weight. It is an important raw material for the production of iron hydroxide from sucrose. Gongji Chemicals has leading technology and is currently one of the domestic manufacturers of ultra-high purity iron trichloride.